Withings Acquires Biosency for Respiratory Health Expansion

Withings, a prominent player in connected health technology, has finalized the acquisition of Biosency, a French medtech firm specializing in remote monitoring for respiratory insufficiency. This strategic move significantly expands Withings' footprint into the vital area of respiratory telehealth, integrating Biosency's expertise into its growing portfolio of predictive health solutions.

The acquisition marks a pivotal moment for Biosency, which had recently faced financial headwinds, including being placed under judicial administration. The integration with Withings provides a robust platform for Biosency's technology, ensuring its continued development and market penetration. The Biosency team will remain in Rennes, continuing their work under the Withings umbrella, fostering innovation within the region.

Éric Carreel, founder and president of Withings, highlighted the strong synergy between the two companies. "I see a strong alignment between detecting respiratory decompensations and the work we are doing on monitoring cardio-metabolic diseases," Carreel stated. "This operation is part of our ambition to build a strong and independent European health player." This sentiment underscores Withings' commitment to comprehensive, proactive healthcare management.

Biosency's core offering focuses on remote monitoring for chronic respiratory conditions, such as Chronic Obstructive Pulmonary Disease (COPD). This technology complements Withings' existing suite of innovative health devices, which aim to provide daily health check-ups and early disease detection. The company recently showcased its advanced Body Scan smart scale at CES, capable of analyzing 60 biomarkers in 90 seconds, demonstrating its dedication to accessible, data-driven health insights.

The integration of Biosency's respiratory monitoring capabilities is particularly timely. The global market for remote patient monitoring is experiencing substantial growth, driven by an aging population and the increasing prevalence of chronic diseases. Industry analysts project the remote patient monitoring market to reach tens of billions of dollars in the coming years, with respiratory care representing a significant segment. Withings' acquisition positions it to capture a larger share of this expanding market.

This acquisition is not just about expanding product lines; it's about consolidating a vision for integrated digital health. By bringing Biosency's specialized knowledge into its fold, Withings strengthens its ability to offer end-to-end solutions for managing complex health conditions. The move signals a clear strategy to become a leading European force in independent digital health, leveraging connected devices and advanced data analytics to improve patient outcomes and reduce healthcare system burdens.